argenx SE ADR ARGX
News
Argenx to Buy Unnatural Products for Up to $1.15 Billion
argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
argenx to Present at Upcoming Investor Conferences
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)
argenx Down Nearly 13%, on Pace for Largest Percent Decrease Since December 2023 — Data Talk
Argenx Shares Plunge After Autoimmune-Disease Trial Halt
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
argenx to Present at Upcoming Investor Conferences
argenx Completes Acquisition of Forte Biosciences, Inc.


